|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
CA1291706C
(en)
|
1986-04-03 |
1991-11-05 |
Alfred Rudolph |
COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
|
|
CA1290249C
(en)
|
1986-04-09 |
1991-10-08 |
Cetus Corporation |
COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
CA1341374C
(en)
|
1986-11-13 |
2002-07-09 |
Alan N. Houghton |
Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
EP0379522B1
(en)
|
1987-09-22 |
1995-05-03 |
Cetus Oncology Corporation |
Uses of recombinant colony stimulating factor-1
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
US4999339A
(en)
|
1988-03-28 |
1991-03-12 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
|
US5061488A
(en)
|
1988-04-15 |
1991-10-29 |
The United States Of America As Represented Department Of Health & Human Services |
Flavone-8-acetic acid and interleukin-2 for cancer therapy
|
|
US5126129A
(en)
|
1988-05-23 |
1992-06-30 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services |
Cancer therapy using interleukin-2 and flavone compounds
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
KR100246529B1
(ko)
|
1990-12-14 |
2000-04-01 |
스티븐 에이. 서윈. 엠.디. |
수용체 관련된 신호 변환 경로를 위한 키메라 사슬
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
US5229109A
(en)
*
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
US5306490A
(en)
|
1992-04-20 |
1994-04-26 |
Medlogic, Inc. |
Methods for retarding blister formation by use of cyanoacrylate adhesives
|
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
WO1994004196A1
(en)
|
1992-08-14 |
1994-03-03 |
Imperial Cancer Research Technology Limited |
Tumour therapy
|
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5834441A
(en)
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
WO1995029193A2
(en)
|
1994-04-22 |
1995-11-02 |
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services |
Melanoma antigens
|
|
JPH10503371A
(ja)
|
1994-07-29 |
1998-03-31 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
新規化合物
|
|
JPH11501506A
(ja)
|
1994-12-12 |
1999-02-09 |
ベス イスラエル デアコネス メディカル センター |
キメラ型サイトカインおよびその利用
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
WO1996040176A1
(en)
|
1995-06-07 |
1996-12-19 |
Sloan-Kettering Institute For Cancer Research |
Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells
|
|
US5985270A
(en)
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
|
US6406689B1
(en)
|
1995-10-03 |
2002-06-18 |
Frank W. Falkenberg |
Compositions and methods for treatment of tumors and metastatic diseases
|
|
US6045788A
(en)
|
1996-02-28 |
2000-04-04 |
Cornell Research Foundation, Inc. |
Method of stimulation of immune response with low doses of IL-2
|
|
AU728657B2
(en)
|
1996-03-18 |
2001-01-18 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1997042217A1
(en)
|
1996-05-06 |
1997-11-13 |
The Uab Research Foundation |
Radiolabeled fusion toxins for cancer therapy
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
CA2309766C
(en)
|
1997-11-20 |
2008-09-30 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
|
US20030105294A1
(en)
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
PL199659B1
(pl)
|
1998-02-25 |
2008-10-31 |
Merck Patent Gmbh |
Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
PT2180007E
(pt)
|
1998-04-20 |
2013-11-25 |
Roche Glycart Ag |
Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6620382B1
(en)
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
|
US6168785B1
(en)
|
1998-07-16 |
2001-01-02 |
Institut Pasteur |
Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
|
|
US6013659A
(en)
|
1998-09-04 |
2000-01-11 |
University Of Pittsburgh |
Methods of reducing tumor colony number using novel benzothiazole compounds
|
|
EP1143957A3
(en)
|
1998-12-16 |
2002-02-27 |
Warner-Lambert Company |
Treatment of arthritis with mek inhibitors
|
|
KR101155191B1
(ko)
|
1999-01-15 |
2012-06-13 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US7115261B1
(en)
|
1999-02-12 |
2006-10-03 |
The Scripps Research Institute |
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
|
|
US20020058609A1
(en)
|
1999-02-26 |
2002-05-16 |
Eli Gilboa |
Compositions and methods using complexes of calreticulin and antigenic molecules
|
|
WO2000059515A2
(en)
|
1999-04-02 |
2000-10-12 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
|
TWI310314B
(en)
|
1999-04-08 |
2009-06-01 |
Schering Corp |
Pharmaceutical compositions for treating rental cell carcinoma
|
|
ES2568899T3
(es)
|
1999-04-09 |
2016-05-05 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
|
DE60025832T2
(de)
|
1999-08-09 |
2006-08-31 |
Emd Lexigen Research Center Corp., Billerica |
Mehrere zytokin-antikörper komplexen
|
|
WO2001014424A2
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
ATE305801T1
(de)
|
2000-01-20 |
2005-10-15 |
Univ Zuerich Inst Fuer Medizin |
Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
|
|
WO2001074847A2
(en)
|
2000-03-30 |
2001-10-11 |
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services |
T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
|
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
ATE440618T1
(de)
|
2000-06-22 |
2009-09-15 |
Univ Iowa Res Found |
Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
|
|
NZ524120A
(en)
|
2000-07-19 |
2005-08-26 |
Warner Lambert Co |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
WO2004007529A2
(en)
|
2002-07-15 |
2004-01-22 |
The Trustees Of Princeton University |
Iap binding compounds
|
|
AU2002223350A1
(en)
|
2000-12-01 |
2002-06-11 |
Eleanor N. Fish |
Cytokine receptor binding peptides
|
|
US20040253242A1
(en)
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
|
DE60136656D1
(de)
|
2000-12-05 |
2009-01-02 |
Alexion Pharma Inc |
Rationell entworfene Antikörper
|
|
IL140796A0
(en)
|
2001-01-08 |
2002-02-10 |
Hadasit Med Res Service |
An autologous anti-cancer vaccine
|
|
CA2438628A1
(en)
|
2001-02-19 |
2002-08-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Artificial proteins with reduced immunogenicity
|
|
RU2003129528A
(ru)
|
2001-03-07 |
2005-04-10 |
Мерк Патент ГмбХ (DE) |
Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
|
|
DE60239454D1
(de)
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
|
WO2002097044A2
(en)
|
2001-05-25 |
2002-12-05 |
Thomas Jefferson University |
Alternative splice forms of proteins as basis for multiple therapeutic modalities
|
|
FR2825279B1
(fr)
|
2001-06-01 |
2005-04-08 |
Molecular Engines Lab |
Medicament utile dans le traitement du cancer
|
|
JP2005507870A
(ja)
|
2001-08-13 |
2005-03-24 |
ユニバーシティ・オブ・サザン・カリフォルニア |
低毒性のインターロイキン−２突然変異体
|
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
US20060084123A1
(en)
|
2001-12-13 |
2006-04-20 |
Harris Adrian L |
MN and hypoxia
|
|
WO2003064383A2
(en)
|
2002-02-01 |
2003-08-07 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing compounds & uses thereof
|
|
EP1483294B2
(en)
*
|
2002-03-01 |
2019-10-30 |
Immunomedics, Inc. |
Internalizing anti-cd74 antibodies and methods of use
|
|
CA2478065C
(en)
|
2002-03-08 |
2013-01-08 |
Eisai Co. Ltd. |
Macrocyclic compounds useful as pharmaceuticals
|
|
WO2003082212A2
(en)
|
2002-03-27 |
2003-10-09 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Method for treating cancer in humans
|
|
JP4421900B2
(ja)
|
2002-04-09 |
2010-02-24 |
ザ スクリップス リサーチ インスティテュート |
モチーフ・グラフトされたハイブリッドポリペプチドおよびその使用
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
NZ536908A
(en)
|
2002-05-17 |
2008-09-26 |
Celgene Corp |
Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
|
|
SI1505973T1
(sl)
|
2002-05-17 |
2010-06-30 |
Celgene Corp |
Kombinacija za zdravljenje multiplega mieloma
|
|
EP1524995B1
(en)
|
2002-07-01 |
2011-12-21 |
Wilex AG |
Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
|
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
WO2004020468A2
(en)
|
2002-08-28 |
2004-03-11 |
Maxygen Aps |
Interferon beta-like molecules for treatment of cancer
|
|
ES2602145T3
(es)
|
2002-09-06 |
2017-02-17 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa
|
|
WO2004022747A1
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20040121971A1
(en)
|
2002-12-20 |
2004-06-24 |
Gang Chen |
Therapeutic use of tumor necrosis factor-alpha mutein
|
|
WO2004056392A1
(en)
|
2002-12-23 |
2004-07-08 |
Innate Pharma |
Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
|
EP1656124A1
(en)
|
2003-03-12 |
2006-05-17 |
Cerenis |
Methods and compositions for the treatment of cancer
|
|
US20070243159A1
(en)
|
2003-04-30 |
2007-10-18 |
Periasamy Selvaraj |
Therapeutic Compositions and Vaccines By Glycosyl-Phosphatidylinositol (Gpi)-Anchored Cytokines and Immunostimulatory Molecules
|
|
EP1643971A2
(en)
|
2003-05-22 |
2006-04-12 |
Neopharm, Inc. |
Liposomal formulations comprising a combination of two or more active agents
|
|
WO2004108078A2
(en)
|
2003-06-02 |
2004-12-16 |
Alexion Pharmaceuticals Inc. |
Rationally designed antibodies
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
CN103173354B
(zh)
|
2003-10-08 |
2017-07-14 |
威尔森沃尔夫制造公司 |
利用透气性材料进行细胞培养的方法及装置
|
|
DK1684805T3
(da)
|
2003-11-04 |
2010-10-04 |
Novartis Vaccines & Diagnostic |
Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
|
|
US7259249B2
(en)
|
2003-12-01 |
2007-08-21 |
Immunomedics, Inc. |
Method for preparing conjugates of proteins and chelating agents
|
|
CN100467488C
(zh)
|
2003-12-30 |
2009-03-11 |
默克专利有限公司 |
Il-7融合蛋白
|
|
CN1960728A
(zh)
|
2004-01-16 |
2007-05-09 |
密歇根大学董事会 |
构象受限的smac模拟物及其应用
|
|
WO2005069888A2
(en)
|
2004-01-16 |
2005-08-04 |
The Regents Of The University Of Michigan |
Smac peptidomimetics and the uses thereof
|
|
JP4782700B2
(ja)
|
2004-01-20 |
2011-09-28 |
カロバイオス ファーマシューティカルズ インコーポレイティッド |
最低限必須な結合決定基を用いた抗体特異性の移入
|
|
CN1964716A
(zh)
|
2004-02-26 |
2007-05-16 |
伊诺泰克制药公司 |
异喹啉衍生物及其使用方法
|
|
JP5122275B2
(ja)
|
2004-03-23 |
2013-01-16 |
ジェネンテック， インコーポレイテッド |
Ｉａｐのアザビシクロ−オクタンインヒビター
|
|
ME02125B
(me)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
WO2006014361A1
(en)
|
2004-07-02 |
2006-02-09 |
Genentech, Inc. |
Inhibitors of iap
|
|
US7674787B2
(en)
|
2004-07-09 |
2010-03-09 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
EP2457895A1
(en)
|
2004-07-12 |
2012-05-30 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
|
ES2475207T3
(es)
|
2004-07-15 |
2014-07-10 |
Tetralogic Pharmaceuticals Corporation |
Compuestos de unión a IAP
|
|
CN1721533A
(zh)
|
2004-07-16 |
2006-01-18 |
中国科学院沈阳应用生态研究所 |
Il2与抗gd2单链抗体融合蛋白及编码基因和应用
|
|
CA2574572A1
(en)
|
2004-07-19 |
2006-10-26 |
Baylor College Of Medicine |
Modulation of cytokine signaling regulators and applications for immunotherapy
|
|
CA2578205A1
(en)
|
2004-08-25 |
2006-03-30 |
The Regents Of The University Of Michigan |
Partially acetylated dendrimers and related methods of use
|
|
EP1640018A1
(en)
|
2004-09-24 |
2006-03-29 |
Universität Zürich |
Combinational therapy for treating cancer
|
|
CA2943949C
(en)
|
2004-10-06 |
2020-03-31 |
Mayo Foundation For Medical Education And Research |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
|
|
US20060115485A1
(en)
|
2004-10-29 |
2006-06-01 |
Medimmune, Inc. |
Methods of preventing and treating RSV infections and related conditions
|
|
EP1824987B1
(en)
|
2004-11-16 |
2013-08-21 |
KaloBios Pharmaceuticals, Inc. |
Immunoglobulin variable region cassette exchange
|
|
CU23297A1
(es)
|
2004-11-16 |
2008-07-24 |
Ct De Inmunologa A Molecular |
Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
|
|
US7589179B2
(en)
|
2004-12-09 |
2009-09-15 |
Merck Patent Gmbh |
IL-7 variants with reduced immunogenicity
|
|
ATE477254T1
(de)
|
2004-12-20 |
2010-08-15 |
Genentech Inc |
Pyrrolidine als inhibitoren von iap
|
|
MX2007009012A
(es)
|
2005-01-27 |
2007-09-14 |
Novartis Vaccines & Diagnostic |
Metodos para tratar carcinoma de celulas renales.
|
|
ATE367167T1
(de)
|
2005-02-07 |
2007-08-15 |
Novartis Vaccines & Diagnostic |
Aufbereitung von aldesleukin zur pharmazeutischen verwendung
|
|
AU2006214138A1
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Antiangiogenic agents with aldesleukin
|
|
PL1851250T3
(pl)
|
2005-02-18 |
2012-10-31 |
Squibb & Sons Llc |
Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA)
|
|
KR20070116016A
(ko)
|
2005-02-25 |
2007-12-06 |
이노텍 파마슈티컬스 코포레이션 |
이소퀴놀린 화합물 및 그의 이용 방법
|
|
JP2008531563A
(ja)
|
2005-02-25 |
2008-08-14 |
イノテック ファーマシューティカルズ コーポレイション |
四環スルホンアミド化合物およびこれらの使用法
|
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
|
CA2608463C
(en)
|
2005-05-19 |
2015-02-03 |
Prometic Biosciences Inc. |
Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
EP1912677B1
(en)
|
2005-06-20 |
2013-10-02 |
Psma Development Company, L.L.C. |
PSMA antibody-drug conjugates
|
|
RS54271B1
(sr)
|
2005-07-01 |
2016-02-29 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
|
|
ES2481402T3
(es)
|
2005-07-21 |
2014-07-30 |
Ardea Biosciences, Inc. |
Inhibidores de N-(arilamino)sulfonamida de MEK
|
|
AU2006287441B2
(en)
|
2005-09-07 |
2012-09-06 |
Sillajen Biotherapeutics, Inc. |
Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
|
|
EP1928471A2
(en)
|
2005-09-26 |
2008-06-11 |
Novacea, Inc. |
Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds
|
|
WO2007051119A1
(en)
|
2005-10-26 |
2007-05-03 |
Mgi Gp, Inc. |
Methods and compositions of parp inhibitors as potentiators in cancer therapy
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
BRPI0708446A2
(pt)
|
2006-03-01 |
2011-06-07 |
Janssen Pharmaceutica Nv |
tratamento de cáncer combinando agente de linfodepleção com ctls e citocinas
|
|
CA2656700A1
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
|
US8119772B2
(en)
|
2006-09-29 |
2012-02-21 |
California Institute Of Technology |
MART-1 T cell receptors
|
|
WO2008051220A1
(en)
|
2006-10-24 |
2008-05-02 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Interaction of il-27 and il-2 for treatment of tumors
|
|
US20080221551A1
(en)
|
2007-03-09 |
2008-09-11 |
Flowmedica, Inc. |
Acute kidney injury treatment systems and methods
|
|
KR20090119768A
(ko)
|
2007-03-09 |
2009-11-19 |
노파르티스 아게 |
흑색종 치료법
|
|
AU2008226337B2
(en)
|
2007-03-14 |
2012-02-16 |
BioLingus IP II GmbH |
Method for treating cancer via the mucosal administration of interleukin
|
|
BRPI0809867A2
(pt)
|
2007-04-30 |
2014-09-30 |
Genentech Inc |
Composto, método de indução da apoptose em uma célula, método de sensibilização de uma célula para um sinal apoptótico, método para inibir a ligação de uma proteína iap a uma proteína caspase e métodos
|
|
US20100189681A1
(en)
|
2007-06-01 |
2010-07-29 |
Innate Pharma S.A. |
Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer
|
|
NZ582150A
(en)
|
2007-06-18 |
2012-08-31 |
Msd Oss Bv |
Antibodies to human programmed death receptor pd-1
|
|
EP2205242B1
(en)
|
2007-09-12 |
2015-04-15 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
SI2209375T1
(sl)
|
2007-10-03 |
2014-12-31 |
Eisai Inc. |
Spojine inhibitorja PARP in metode uporabe
|
|
EP2050458A1
(en)
|
2007-10-17 |
2009-04-22 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL24 for inducing hyperproliferative or autoimmune cell death
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
WO2009088805A2
(en)
|
2008-01-03 |
2009-07-16 |
The Scripps Research Institute |
Antibody targeting through a modular recognition domain
|
|
US20140127200A1
(en)
|
2008-01-03 |
2014-05-08 |
The Scripps Research Institute |
Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
|
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
|
MX2010008786A
(es)
|
2008-02-11 |
2010-12-01 |
Curetech Ltd |
Anticuerpos monoclonales para tratamiento de tumores.
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
WO2009152610A1
(en)
|
2008-06-20 |
2009-12-23 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
GB0815216D0
(en)
|
2008-08-21 |
2008-09-24 |
Asterion Ltd |
Interleukin
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
WO2010042765A1
(en)
|
2008-10-08 |
2010-04-15 |
The Regents Of The University Of California |
Ca9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma
|
|
CN108635350A
(zh)
|
2009-01-12 |
2018-10-12 |
爱尔皮奥治疗有限公司 |
治疗血管渗漏综合征的方法
|
|
JP2012518408A
(ja)
|
2009-02-24 |
2012-08-16 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体
|
|
EP2429585B1
(en)
|
2009-05-15 |
2018-04-18 |
IRX Therapeutics, Inc. |
Vaccine immunotherapy
|
|
US9005575B2
(en)
|
2009-06-12 |
2015-04-14 |
Stc.Unm |
Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
|
|
CA2769619C
(en)
|
2009-08-17 |
2019-04-30 |
Roche Glycart Ag |
Targeted immunoconjugates
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
WO2011031865A1
(en)
|
2009-09-09 |
2011-03-17 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
US8986651B2
(en)
|
2009-11-30 |
2015-03-24 |
Stc.Unm |
Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
EP2698430A3
(en)
|
2009-12-08 |
2014-03-05 |
Wilson Wolf Manufacturing Corporation |
Methods of cell culture for adoptive cell therapy
|
|
EP3075390A1
(en)
|
2010-01-19 |
2016-10-05 |
Immunomedics Inc. |
Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
|
|
WO2011139738A2
(en)
|
2010-04-28 |
2011-11-10 |
Tenx Biopharma, Inc. |
Therapies using zanolimumab to enhance the immune response
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
WO2012021609A2
(en)
|
2010-08-12 |
2012-02-16 |
Ulrik Mouritzen |
Neoadjuvant treatment of cancer with proleukin
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|
|
US20120201750A1
(en)
|
2010-09-20 |
2012-08-09 |
Bungwoo Ryu |
Serum biomarkers for melanoma metastasis
|
|
WO2012045334A1
(en)
|
2010-10-05 |
2012-04-12 |
Synthon Bv |
Biologically active il-10 fusion proteins
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
EP2673294B1
(en)
*
|
2011-02-10 |
2016-04-27 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
|
MX2013009151A
(es)
|
2011-02-10 |
2013-08-29 |
Roche Glycart Ag |
Inmunoterapia mejorada.
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
ES2758884T3
(es)
|
2011-06-24 |
2020-05-06 |
Stephen D Gillies |
Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
|
|
WO2013044169A1
(en)
|
2011-09-21 |
2013-03-28 |
Nestec S.A. |
Methods for determining combination therapy with il-2 for the treatment of cancer
|
|
ES2762179T3
(es)
|
2011-09-26 |
2020-05-22 |
Philogen Spa |
Terapia de combinación de inmunocitocinas
|
|
EP3505182A1
(en)
|
2011-10-13 |
2019-07-03 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
|
AU2012324644B2
(en)
|
2011-10-21 |
2014-08-28 |
Cell Medica Limited |
Device for the aseptic expansion of cells
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
|
WO2013106485A2
(en)
*
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
RU2633638C2
(ru)
|
2012-02-02 |
2017-10-16 |
Акселерон Фарма Инк. |
Антагонисты alk1 и их применение в лечении почечно-клеточной карциномы
|
|
KR20190134832A
(ko)
|
2012-03-29 |
2019-12-04 |
알토 바이오사이언스 코포레이션 |
종양 형성 치료방법
|
|
EP2846816B1
(en)
|
2012-05-08 |
2016-09-28 |
The Johns Hopkins University |
Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
|
|
SG10202111564SA
(en)
|
2012-05-18 |
2021-12-30 |
Wilson Wolf Mfg Corporation |
Improved methods of cell culture for adoptive cell therapy
|
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
|
EP2859093A4
(en)
|
2012-06-11 |
2016-08-17 |
Wolf Wilson Mfg Corp |
IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
CN104540848B
(zh)
|
2012-08-08 |
2019-05-31 |
罗切格利卡特公司 |
白介素-10融合蛋白及其用途
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9970936B2
(en)
|
2012-11-13 |
2018-05-15 |
Mayo Foundation For Medical Education And Research |
Methods and materials for assessing immune system profiles
|
|
CN105073781A
(zh)
|
2013-01-11 |
2015-11-18 |
加州生物医学研究所 |
牛融合抗体
|
|
CN111643524B
(zh)
|
2013-03-01 |
2023-09-05 |
美国卫生和人力服务部 |
从外周血中产生肿瘤反应性t细胞富集群的方法
|
|
CA2902423C
(en)
|
2013-03-01 |
2021-06-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
AU2014225307A1
(en)
|
2013-03-08 |
2015-09-24 |
The Curators Of The University Of Missouri |
Methods and compositions for the treatment and/or prevention of type 1 diabetes
|
|
WO2014152122A2
(en)
|
2013-03-15 |
2014-09-25 |
Children's Medical Center Corporation |
Methods of altering vascular permeability and uses thereof
|
|
US20150017120A1
(en)
|
2013-06-13 |
2015-01-15 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
|
|
CN118562610A
(zh)
|
2013-06-24 |
2024-08-30 |
威尔逊沃夫制造公司 |
用于透气性细胞培养过程的封闭系统装置和方法
|
|
CN112225817B
(zh)
|
2013-07-11 |
2025-02-25 |
斯克利普斯研究所 |
卷曲螺旋免疫球蛋白融合蛋白及其组合物
|
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
US9572828B2
(en)
|
2013-07-18 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
US10640574B2
(en)
|
2013-07-18 |
2020-05-05 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementary determining regions
|
|
US10233425B2
(en)
|
2013-09-16 |
2019-03-19 |
The Trustees Of The University Of Pennsylvania |
CD137 enrichment for efficient tumor infiltrating lymphocyte selection
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
RU2016135788A
(ru)
|
2014-02-06 |
2018-03-07 |
Ф.Хоффманн-Ля Рош Аг |
Иммуноконъюгаты интерлейкина 10
|
|
BR112016018288A2
(pt)
|
2014-02-06 |
2017-10-10 |
Hoffmann La Roche |
proteínas de fusão de interleucina 2 e uso das mesmas
|
|
WO2015134577A1
(en)
|
2014-03-06 |
2015-09-11 |
Morphogenesis, Inc. |
Dna vector and transformed tumor cell vaccines
|
|
WO2015140150A1
(en)
|
2014-03-17 |
2015-09-24 |
Piotr Jachimczak |
Combination for use in a method of treating cancer
|
|
CA2942610C
(en)
|
2014-03-17 |
2024-02-20 |
Richard Kroczek |
Use of a medicament comprising a peptide-loaded peripheral blood mononuclear cell for extending a cellular cytotoxic immune response
|
|
CA2943389C
(en)
|
2014-03-20 |
2023-10-31 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
EP3154350B1
(en)
|
2014-04-10 |
2024-03-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
MX389827B
(es)
|
2014-06-11 |
2025-03-20 |
Polybiocept Gmbh |
Composición para expandir in vitro linfocitos que tiene interleucina 2 (il-2), interleucina 15 (il-15) e interleucina 21 (il-21).
|
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
US20170218042A1
(en)
|
2014-10-02 |
2017-08-03 |
The United State of America, as represented by the Secretary, Department of Health and Human Service |
Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
AU2015338974B2
(en)
|
2014-10-31 |
2021-08-26 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
GB201419976D0
(en)
|
2014-11-10 |
2014-12-24 |
Univ Newcastle |
Biomarkers for disease progression in melanoma
|
|
EP3034092A1
(en)
|
2014-12-17 |
2016-06-22 |
Université de Lausanne |
Adoptive immunotherapy for treating cancer
|
|
CU20180047A7
(es)
*
|
2015-12-04 |
2018-07-05 |
Novartis Ag |
Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
|
|
US20190256840A1
(en)
|
2016-01-08 |
2019-08-22 |
Iontas Ltd |
Binding members with altered diversity scaffold domains
|
|
SMT202400133T1
(it)
|
2016-10-26 |
2024-05-14 |
Iovance Biotherapeutics Inc |
Restimolazione di linfociti infiltranti il tumore crioconservati
|
|
US12006354B2
(en)
*
|
2017-05-24 |
2024-06-11 |
Novartis Ag |
Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
|